XML 23 R13.htm IDEA: XBRL DOCUMENT
v3.22.2.2

Supplementary Balance Sheet Information | 9 Months Ended
--- | ---
Sep. 30, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract] |
Supplementary Balance Sheet Information | Supplementary Balance Sheet Information Investments available for sale Investments available for sale consist of the following:
| As of September 30, 2022
(in thousands) | Amortized Cost |  | Gross Unrealized Gains |  | Gross Unrealized Losses |  | Fair Market Value
Maturity less than 1 year: |  |  |  |  |  |  |
Certificate of deposit | $ | 14,285 |  |  | $ | 4 |  |  | $ | (87) |  |  | $ | 14,202 |
Corporate debt securities | 49,055 |  |  | 3 |  |  | (498) |  |  | 48,560 |
Commercial paper | 10,528 |  |  | 4 |  |  | (49) |  |  | 10,483 |
U.S. treasury securities | 15,348 |  |  | — |  |  | (94) |  |  | 15,254 |
Total maturity less than 1 year | 89,216 |  |  | 11 |  |  | (728) |  |  | 88,499 |
Maturity 1 to 2 years: |  |  |  |  |  |  |
Corporate debt securities | 7,148 |  |  | 4 |  |  | (65) |  |  | 7,087 |
U.S. treasury securities | — |  |  | — |  |  | — |  |  | — |
Total maturity 1 to 2 years | 7,148 |  |  | 4 |  |  | (65) |  |  | 7,087 |
Total short-term investments | $ | 96,364 |  |  | $ | 15 |  |  | $ | (793) |  |  | $ | 95,586 |
| As of December 31, 2021
(in thousands) | Amortized Cost |  | Gross Unrealized Gains |  | Gross Unrealized Losses |  | Fair Market Value
Maturity less than 1 year: |  |  |  |  |  |  |
Certificate of deposit | $ | 1,260 |  |  | $ | — |  |  | $ | — |  |  | $ | 1,260 |
Corporate debt securities | 58,822 |  |  | 2 |  |  | (38) |  |  | 58,786 |
Commercial paper | 14,453 |  |  | 4 |  |  | (3) |  |  | 14,454 |
Non U.S. government | 728 |  |  | — |  |  | — |  |  | 728 |
U.S. treasury securities | 20,380 |  |  | — |  |  | (24) |  |  | 20,356 |
Total maturity less than 1 year | 95,643 |  |  | 6 |  |  | (65) |  |  | 95,584 |
Maturity 1 to 2 years: |  |  |  |  |  |  |
Corporate debt securities | 29,676 |  |  | 1 |  |  | (73) |  |  | 29,604 |
U.S. treasury securities | 3,701 |  |  | — |  |  | (11) |  |  | 3,690 |
Total maturity 1 to 2 years | 33,377 |  |  | 1 |  |  | (84) |  |  | 33,294 |
Total short-term investments | $ | 129,020 |  |  | $ | 7 |  |  | $ | (149) |  |  | $ | 128,878 |
Unrealized losses in investments available for sale debt securities at September 30, 2022, were primarily due to increases in interest rates, not due to increased credit risks associated with specific securities. We do not intend to sell these investments and it is not more likely than not that we will be required to sell the investments before recovery of their amortized cost bases, which may be at maturity. Investments available for sale that have been in a continuous unrealized loss position for greater than one-year consist of the following:
| As of September 30, 2022
(in thousands) | Fair Market Value |  | Gross Unrealized Loss
Corporate debt securities | 751 |  |  | (6) |
U.S. treasury securities | 1,839 |  |  | (22) |
Total short-term investments | $ | 2,590 |  |  | $ | (28) |
Property and equipment Property and equipment consist of the following:
(in thousands) | As of September 30, 2022 |  | As of December 31, 2021
Furniture and office equipment | $ | 1,069 |  |  | $ | 955 |
Leasehold improvements | 2,545 |  |  | 1,962 |
Laboratory equipment | 1,019 |  |  | 906 |
| 4,633 |  |  | 3,823 |
Less—accumulated depreciation and amortization | (3,329) |  |  | (3,441) |
Property and equipment, net | $ | 1,304 |  |  | $ | 382 |
Accrued Liabilities Accrued liabilities consisted of the following:
(in thousands) | As of September 30, 2022 |  | As of December 31, 2021
Accrued compensation | $ | 1,609 |  |  | $ | 1,435 |
Preferred stock dividend | 432 |  |  | 414 |
Clinical trials | 2,132 |  |  | 1,639 |
Research agreements and services | 1,125 |  |  | 726 |
Director fees | 125 |  |  | 141 |
Professional fees and outside services | 29 |  |  | 63 |
Patent, license and other fees | 122 |  |  | 43 |
Other accrued liabilities | 564 |  |  | 66 |
Total accrued liabilities | $ | 6,138 |  |  | $ | 4,527 |

X
- References No definition available. + Details
Name: | us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 958 -SubTopic 360 -Section 50 -Paragraph 6 -URI http://asc.fasb.org/extlink&oid=120429125&loc=d3e99893-112916 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 360 -URI http://asc.fasb.org/topic&trid=2155823 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 958 -SubTopic 360 -Section 50 -Paragraph 7 -URI http://asc.fasb.org/extlink&oid=120429125&loc=SL120174063-112916 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 958 -SubTopic 360 -Section 50 -Paragraph 1 -Subparagraph (d) -URI http://asc.fasb.org/extlink&oid=120429125&loc=d3e99779-112916 + Details
Name: | us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration